Modality
Small Molecule
MOA
C5i
Target
IL-23
Pathway
DDR
FLNSCLCCTCL
Development Pipeline
Preclinical
~Dec 2018
→ ~Mar 2020
Phase 1
~Jun 2020
→ ~Sep 2021
Phase 2
Dec 2021
→ Aug 2031
Phase 2Current
NCT04125695
1,392 pts·FL
2021-12→2031-08·Terminated
1,392 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-08-265.4y awayPh2 Data· FL
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Termina…
Catalysts
Ph2 Data
2031-08-26 · 5.4y away
FL
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04125695 | Phase 2 | FL | Terminated | 1392 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| Fixalucimab | Innovent Bio | Phase 1/2 | IL-23 | |
| Gelisertib | Samsung Biologics | Approved | IL-23 | |
| Talafotisoran | Blueprint Medicines | Phase 2/3 | IL-23 | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 |